Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. More Details
Flawless balance sheet with solid track record and pays a dividend.
Share Price & News
How has Aurobindo Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AUROPHARMA is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AUROPHARMA's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AUROPHARMA underperformed the Indian Pharmaceuticals industry which returned 46.9% over the past year.
Return vs Market: AUROPHARMA underperformed the Indian Market which returned 67.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aurobindo Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAurobindo Pharma's (NSE:AUROPHARMA) Solid Profits Have Weak Fundamentals
1 week ago | Simply Wall StCalculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
4 weeks ago | Simply Wall StI Ran A Stock Scan For Earnings Growth And Aurobindo Pharma (NSE:AUROPHARMA) Passed With Ease
Is Aurobindo Pharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AUROPHARMA (₹994.3) is trading above our estimate of fair value (₹974.27)
Significantly Below Fair Value: AUROPHARMA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AUROPHARMA is good value based on its PE Ratio (10.9x) compared to the Indian Pharmaceuticals industry average (24.2x).
PE vs Market: AUROPHARMA is good value based on its PE Ratio (10.9x) compared to the Indian market (21.6x).
Price to Earnings Growth Ratio
PEG Ratio: AUROPHARMA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: AUROPHARMA is good value based on its PB Ratio (2.7x) compared to the IN Pharmaceuticals industry average (3.1x).
How is Aurobindo Pharma forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUROPHARMA's earnings are forecast to decline over the next 3 years (-8% per year).
Earnings vs Market: AUROPHARMA's earnings are forecast to decline over the next 3 years (-8% per year).
High Growth Earnings: AUROPHARMA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: AUROPHARMA's revenue (7% per year) is forecast to grow slower than the Indian market (12.7% per year).
High Growth Revenue: AUROPHARMA's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AUROPHARMA's Return on Equity is forecast to be low in 3 years time (14.1%).
How has Aurobindo Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AUROPHARMA has a large one-off gain of ₹28.1B impacting its March 31 2021 financial results.
Growing Profit Margin: AUROPHARMA's current net profit margins (21.5%) are higher than last year (12.3%).
Past Earnings Growth Analysis
Earnings Trend: AUROPHARMA's earnings have grown by 15.4% per year over the past 5 years.
Accelerating Growth: AUROPHARMA's earnings growth over the past year (88.4%) exceeds its 5-year average (15.4% per year).
Earnings vs Industry: AUROPHARMA earnings growth over the past year (88.4%) exceeded the Pharmaceuticals industry 51.4%.
Return on Equity
High ROE: AUROPHARMA's Return on Equity (24.3%) is considered high.
How is Aurobindo Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: AUROPHARMA's short term assets (₹198.2B) exceed its short term liabilities (₹106.7B).
Long Term Liabilities: AUROPHARMA's short term assets (₹198.2B) exceed its long term liabilities (₹12.6B).
Debt to Equity History and Analysis
Debt Level: AUROPHARMA's debt to equity ratio (22.2%) is considered satisfactory.
Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 69.1% to 22.2% over the past 5 years.
Debt Coverage: AUROPHARMA's debt is well covered by operating cash flow (68.5%).
Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (57.4x coverage).
What is Aurobindo Pharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AUROPHARMA's dividend (0.4%) is higher than the bottom 25% of dividend payers in the Indian market (0.37%).
High Dividend: AUROPHARMA's dividend (0.4%) is low compared to the top 25% of dividend payers in the Indian market (1.56%).
Stability and Growth of Payments
Stable Dividend: AUROPHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: AUROPHARMA's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (4.4%), AUROPHARMA's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AUROPHARMA's dividends in 3 years are forecast to be thoroughly covered by earnings (8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Narayanan Govindarajan (52 yo)
Mr. Narayanan Govindarajan has been the Managing Director of Aurobindo Pharma Limited since June 1, 2012 and served as its Chief Executive Officer from October 7, 2010 to June 1, 2012. Mr. Govindarajan ser...
CEO Compensation Analysis
Compensation vs Market: Narayanan's total compensation ($USD2.31M) is above average for companies of similar size in the Indian market ($USD818.78K).
Compensation vs Earnings: Narayanan's compensation has been consistent with company performance over the past year.
Experienced Management: AUROPHARMA's management team is seasoned and experienced (6.4 years average tenure).
Experienced Board: AUROPHARMA's board of directors are considered experienced (9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AUROPHARMA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Aurobindo Pharma Limited's company bio, employee growth, exchange listings and data sources
- Name: Aurobindo Pharma Limited
- Ticker: AUROPHARMA
- Exchange: NSEI
- Founded: 1986
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹582.599b
- Shares outstanding: 585.94m
- Website: https://www.aurobindo.com
Number of Employees
- Aurobindo Pharma Limited
- Water Mark Building
- Plot No. 11
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter dru...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/14 16:06|
|End of Day Share Price||2021/06/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.